Integrated 3D-QSAR and Molecular Modeling of Tetrazanbigen Derivatives: Insights into Cellular Antiproliferative Activity and PPARγ Interactions

In this study, CoMFA and CoMSIA models were developed using the reported antiproliferative activities of 34 tetrazanbigen derivatives against LoVo cancer cells. The models were used to investigate structure–activity relationships and to guide the design of six new analogs (P1–P6). Density functional theory calculations, molecular docking, molecular dynamics simulations, and MM/GBSA analyses were subsequently employed to characterize molecular properties and explore the predicted interactions of selected compounds with the PPARγ ligand-binding domain. Importantly, the QSAR models describe cellular antiproliferative activity rather than direct receptor-binding affinity or functional PPARγ activation. Likewise, the structure-based calculations provide computational hypotheses about ligand–receptor interactions but do not establish agonist efficacy or partial agonism. The proposed analogues therefore require experimental evaluation of both antiproliferative activity and PPARγ binding and transactivation before their biological profiles can be established.

Authors

Institutions

Publication Details

Journal
International Journal of Molecular Sciences
Published
2026-11-19
DOI
https://doi.org/10.3390/ijms272210431
Primary Topic
Computational Drug Discovery Methods
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Integrated 3D-QSAR and Molecular Modeling of Tetrazanbigen Derivatives: Insights into Cellular Antiproliferative Activity and PPARγ Interactions

Oussama Chedadi, Belkheir Hammouti, Khalil Azzaoui, Abdelkrim Ouammou et al.
International Journal of Molecular Sciences
Computational Drug Discovery Methods
article

Integrated 3D-QSAR and Molecular Modeling of Tetrazanbigen Derivatives: Insights into Cellular Antiproliferative Activity and PPARγ Interactions

Oussama Chedadi, Belkheir Hammouti, Khalil Azzaoui, Abdelkrim Ouammou, Ahmed El‐Harairy, Lamy Mamdoh Mohamed Hamed, Kamal Moradi, Abdelilah Toughzaoui, Abdeslam Dakhama, Abderrafie Drajou, Hajar El Ouarti, Kamal Laourdani
article en

Abstract

In this study, CoMFA and CoMSIA models were developed using the reported antiproliferative activities of 34 tetrazanbigen derivatives against LoVo cancer cells. The models were used to investigate structure–activity relationships and to guide the design of six new analogs (P1–P6). Density functional theory calculations, molecular docking, molecular dynamics simulations, and MM/GBSA analyses were subsequently employed to characterize molecular properties and explore the predicted interactions of selected compounds with the PPARγ ligand-binding domain. Importantly, the QSAR models describe cellular antiproliferative activity rather than direct receptor-binding affinity or functional PPARγ activation. Likewise, the structure-based calculations provide computational hypotheses about ligand–receptor interactions but do not establish agonist efficacy or partial agonism. The proposed analogues therefore require experimental evaluation of both antiproliferative activity and PPARγ binding and transactivation before their biological profiles can be established.

International Journal of Molecular SciencesVol. 27(22)
University of Nebraska–Lincoln (US), Damietta University (EG), Euro-Mediterranean University of Fes (MA), King Faisal University (SA), Sidi Mohamed Ben Abdellah University (MA)
Computational Drug Discovery Methods
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon